Bupropion and Cigarette-Related Cues in Smokers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-01

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, double-blind, before-after controlled trial to assess changes in regional brain activation in response to cigarette-related cues from before to after treatment with bupropion (vs placebo).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers

NCT00133757

Nicotine Dependence Tobacco Dependence

COMPLETED PHASE1

Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking

NCT00248118

Tobacco Dependence

TERMINATED PHASE2/PHASE3

Bupropion for Hospital-Based Smoking Cessation

NCT00261170

Smoking

COMPLETED PHASE3

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831

Tobacco Use Disorder

COMPLETED PHASE4

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

NCT00304707

Smoking Cessation Alcohol-Related Disorders

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Smoking, Tobacco

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind, before-after controlled trial

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Caregivers

Matching placebo pills

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bupropion

Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.

Group Type EXPERIMENTAL

Bupropion

Intervention Type DRUG

Bupropion 150 mg sustained release

Placebo

Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupropion

Bupropion 150 mg sustained release

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

bupropion HCl Wellbutrin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment-seeking cigarette smoker
* Meet DSM-IV criteria for nicotine dependence
* Negative result on urine test for drug use during screening

Exclusion Criteria

* History of any Axis I psychiatric diagnosis other than nicotine dependence
* Medical conditions that might affect brain function
* Current use of medications that could alter brain function
* Pregnancy
* Current illicit drug use other than occasional use of marijuana

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No